December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
2 citations
,
December 2021 in “Korean Journal of Clinical Pharmacy” 1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
September 2024 in “Journal of Ethnopharmacology” Terminalia bellirica extracts effectively promote hair regrowth and treat androgenetic alopecia.
6 citations
,
October 2012 in “Pediatrics” Serenoa repens (saw palmetto) may cause side effects like hot flashes in children and needs more research for safety in pediatric use.
February 2020 in “Zagazig University Medical Journal” The treatment is effective for mild alopecia areata but often causes mild side effects.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
October 2015 in “Annals of Internal Medicine” Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
5 citations
,
November 2017 in “Asian Journal of Beauty and Cosmetology” Sinapic acid may protect skin cells from UV damage and reduce inflammation, making it a promising anti-aging cosmetic ingredient.
17 citations
,
July 2016 in “The Prostate” Metformin may lower PSA levels, possibly affecting prostate cancer development.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
42 citations
,
January 1998 in “BioDrugs” Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
18 citations
,
January 1976 in “Clinical Science” Minoxidil effectively lowers severe high blood pressure but may cause side effects like increased hair growth.
January 2019 in “FarFar - Pharmacy Repository” Microemulsions improve adapalene's skin absorption for better acne treatment.
4 citations
,
January 1996 in “PubMed” February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.
2 citations
,
January 2015 5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
29 citations
,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
26 citations
,
October 2018 in “Clinical & Translational Oncology” Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.